Abstract
Products of normal and pathologic metabolism can react with proteins to cause covalent modification. When such modifications affect fibrinogen they can potentially alter fibrinogen function. Those that have been best studied are oxidation, nitration, homocysteinylation and glycation. It appears that the clottability of fibrinogen is maintained unless the degree of modification is extensive. However, modest degrees of fibrinogen modification can alter the rate of assembly of fibrin monomers into a fibrin clot and the fiber structure and packing. In addition, some types of modification affect lysine residues that are critical to binding, activation and activity of fibrinolytic enzymes. Any of these alterations could potentially affect the susceptibility of fibrin clots to fibrinolysis, and have been shown to do so in vitro. In the case of homocysteinylation and glycation, good evidence exists that fibrinogen modification affects clot stability in vivo. However, direct evidence is still lacking that these modifications contribute to the increased atherothrombotic risk associated with hyperhomocysteinemia and diabetes.
Keywords: Oxidation, nitration, homocysteinylation, glycation, fibrinolysis
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title: Alterations of Fibrinogen Structure in Human Disease
Volume: 6 Issue: 3
Author(s): M. Hoffman
Affiliation:
Keywords: Oxidation, nitration, homocysteinylation, glycation, fibrinolysis
Abstract: Products of normal and pathologic metabolism can react with proteins to cause covalent modification. When such modifications affect fibrinogen they can potentially alter fibrinogen function. Those that have been best studied are oxidation, nitration, homocysteinylation and glycation. It appears that the clottability of fibrinogen is maintained unless the degree of modification is extensive. However, modest degrees of fibrinogen modification can alter the rate of assembly of fibrin monomers into a fibrin clot and the fiber structure and packing. In addition, some types of modification affect lysine residues that are critical to binding, activation and activity of fibrinolytic enzymes. Any of these alterations could potentially affect the susceptibility of fibrin clots to fibrinolysis, and have been shown to do so in vitro. In the case of homocysteinylation and glycation, good evidence exists that fibrinogen modification affects clot stability in vivo. However, direct evidence is still lacking that these modifications contribute to the increased atherothrombotic risk associated with hyperhomocysteinemia and diabetes.
Export Options
About this article
Cite this article as:
Hoffman M., Alterations of Fibrinogen Structure in Human Disease, Cardiovascular & Hematological Agents in Medicinal Chemistry 2008; 6 (3) . https://dx.doi.org/10.2174/187152508784871981
DOI https://dx.doi.org/10.2174/187152508784871981 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Regulation of Cardiac Nerves: A New Paradigm in The Management of Sudden Cardiac Death?
Current Medicinal Chemistry Hypertension in Pregnancy: Pathophysiology & Management Strategies
Current Pharmaceutical Design Outcomes of Clinical Treatments Among Patients with Diabetes Mellitus in Selangor, Malaysia: A Retrospective Study
Current Diabetes Reviews Sex Differences and Emerging New Risk Factors for Atherosclerosis and Its Thrombotic Complications
Current Pharmaceutical Design Signalling Satiety and Starvation to β-Cell Insulin Secretion
Current Diabetes Reviews B Cells and Beyond: Therapeutic Opportunities Targeting Inflammation
Inflammation & Allergy - Drug Targets (Discontinued) Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a New Biomarker for Non – Acute Kidney Injury (AKI) Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Stabilization of Folding Intermediate States from Alkaline Induced Unfolded State of Bovine Serum Fetuin in Trifluoroethanol and Acetonitrile
Protein & Peptide Letters The Impact of Natural and Synthetic Polymers in Formulating Micro and Nanoparticles for Anti-Diabetic Drugs
Current Drug Delivery Possible Role of NUCB2/nesfatin-1 in Adipogenesis
Current Pharmaceutical Design Type 2 Diabetes, Insulin Secretion and β-Cell Mass
Current Molecular Medicine Left Atrial Appendage Closure -The WATCHMAN Device
Current Cardiology Reviews Synthetic Glucocorticoids: Antenatal Administration and Long-term Implications
Current Pharmaceutical Design Fetal Protein Restriction, Taurine and Islet Plasticity
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Endothelial Microparticles: Mediators or Markers of Endothelial Cell Dysfunction?
Current Hypertension Reviews Raman Spectroscopy and Imaging: Promising Optical Diagnostic Tools in Pediatrics
Current Medicinal Chemistry Editorial (Thematic Issue: Nanotechnology as a Strategy to Improve Treatment of Diabetes)
Current Pharmaceutical Biotechnology The Leukocyte Common Antigen-Related Protein LAR: Candidate PTP for Inhibitory Targeting
Current Topics in Medicinal Chemistry Therapeutic Apheresis in Metabolic Syndrome
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Inflammasomes in the Pathophysiology of Maternal Obesity: Potential Therapeutic Targets to Reduce Long-Term Adverse Health Outcomes in the Mother and Offspring
Current Vascular Pharmacology